Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
about
Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Superior efficacy of rituximab ...... from a single center in China.
@ast
Superior efficacy of rituximab ...... from a single center in China.
@en
type
label
Superior efficacy of rituximab ...... from a single center in China.
@ast
Superior efficacy of rituximab ...... from a single center in China.
@en
prefLabel
Superior efficacy of rituximab ...... from a single center in China.
@ast
Superior efficacy of rituximab ...... from a single center in China.
@en
P2093
P2860
P1433
P1476
Superior efficacy of rituximab ...... from a single center in China
@en
P2093
Junyuan Qi
Xiaoyan Feng
Zengjun Li
P2860
P2888
P356
10.1186/S12885-015-1534-0
P407
P577
2015-07-29T00:00:00Z
P5875
P6179
1011837085